Literature DB >> 14751759

Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.

Fumihiko Takeshita1, Ihsan Gursel, Ken J Ishii, Koichi Suzuki, Mayda Gursel, Dennis M Klinman.   

Abstract

Synthetic oligodeoxynucleotides (ODN) expressing non-methylated "CpG motifs" patterned after those present in bacterial DNA have characteristic immunomodulatory effects. CpG DNA is recognized as a pathogen-associated molecular pattern, and triggers a rapid innate immune response. CpG ODN are being harnessed for a variety of therapeutic uses, including as immune adjuvants, for cancer therapy, as anti-allergens, and as immunoprotective agents. The signal transduction pathway mediated by the engagement of CpG DNA with Toll-like receptor 9 (TLR9) is shared with other members of the TLR family. Recent studies demonstrate that formation and maturation of CpG DNA-containing endosomes are regulated by phosphatidylinositol 3 kinases and the Ras-associated GTP-binding protein, Rab5, which are essential for the initiation of TLR9-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751759     DOI: 10.1016/j.smim.2003.10.009

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  64 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

3.  The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells.

Authors:  Geanncarlo Lugo-Villarino; Shu-Ichi Ito; Dennis M Klinman; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-31       Impact factor: 11.205

Review 4.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 5.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

6.  LNA-based oligonucleotide electrotransfer for miRNA inhibition.

Authors:  Sophie Chabot; Julie Orio; Romain Castanier; Elisabeth Bellard; Søren J Nielsen; Muriel Golzio; Justin Teissié
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

7.  Hepatitis A virus adaptation to cellular shutoff is driven by dynamic adjustments of codon usage and results in the selection of populations with altered capsids.

Authors:  M Isabel Costafreda; Francisco J Pérez-Rodriguez; Lucía D'Andrea; Susana Guix; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

9.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.